Sareum Holdings (GB:SAR) has released an update.
Sareum Holdings has announced encouraging results from its Phase 1 clinical trial for SDC-1801, a new treatment for autoimmune diseases, showing achievement of therapeutic blood plasma levels without serious side effects. The successful trial suggests the possibility of once-daily dosing due to the drug’s long half-life and sets the stage for advancing to the next phase of development. Further detailed data on the trial is anticipated to be released in the third quarter of 2024.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
